Skip to main content
SpringerLink
Log in

48-Hour Hemodynamic Effects of Octreotide on Postprandial Splanchnic Hyperemia in Patients with Liver Cirrhosis and Portal Hypertension

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Octreotide is effective during 48 h in the treatment of acute variceal bleeding, probably by reducing variceal blood flow and pressure. Its basal and postprandial effects on splanchnic and systemic hemodynamics, and hormonal changes over this time interval have not yet been studied. Twenty-four patients with cirrhosis and portal hypertension were randomized to receive a liquid meal and either octreotide (Oct, 100 μg bolus intravenous, followed after 2 h by a continuous infusion of 25 μg/hr for 20 hr) or placebo (Plac) given at three consecutive days. Splanchnic (Doppler ultrasound) and systemic hemodynamics (noninvasive cardiac monitoring) were assessed on four consecutive days (one control day and three treatment days) during 2 hr. The postprandial increase in mean blood velocity of the superior mesenteric artery (SMA-V mean, +44%), portal blood velocity (PV-V mean, +44%) and total hepatic blood flow (HBF, +40%) observed in the placebo group during the control day was abolished during the first day of treatment (SMA-Vmean, +3%, P < 0.01; PV-Vmean, +6%, P < 0.05; HBF, −25%, P < 0.01) and still reduced after 48 hr in the octreotide group (SMA-Vmean, +28%, P < 0.05; PV-Vmean, +22%, P > 0.05; HBF, −8%, P < 0.05). The postprandial increase in cardiac index (CI, +10%) and decrease in systemic vascular resistance index (SVRI, −6%) were blunted after the initial injection of octreotide only (CI, −8%, P < 0.05; SVRI, +18%, P < 0.01). Endothelin-1-levels, which were increased at baseline (Plac 25 ± 17, Oct 16 ± 13 ng/liter, P > 0.05) decreased significantly after 48 hr of treatment with octreotide (Plac 27 ± 20, Oct 8 ± 4 ng/liter, P < 0.05). Octreotide is effective during 48 hr in the prevention of postprandial hyperemia in cirrhotics, even if its efficacy is decreasing over time. Moreover it may have positive effects on systemic vasodilation in cirrhotics. These findings suggest a potential role of this drug in the chronic treatment of portal hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D: Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 8:647-651, 1988

    Google Scholar 

  2. Garcia Pagan JC, Santos C, Barbera JA, Luca A, Roca J, Rodriguez-Roisin R, Bosch J, Rodes J: Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 111:1300-1306, 1996

    Google Scholar 

  3. Abillos A, Banares R, Barrios C, Clemente G, Rossi I, Escartin P, Bosch J: Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology 102:248-254, 1992

    Google Scholar 

  4. Iwao T, Oho K, Sakai T, Sato M, Nakano R, Yamayaki M, Toyonaga A, Tanikawa K: Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 28:847-855, 1998

    Google Scholar 

  5. Sabba C, Ferraioli G, Genecin P, Colombato L, Buonamico P, Lerner E, Taylor KJ, Groszmann RJ: Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: An operator-blind echo-Doppler study. Hepatology 13:714-718, 1991

    Google Scholar 

  6. Sung JJ, Chung SC, Lai C-W, Chan FK, Leung JW, Yung M-Y, Kassianides C, Li AK: Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 342:637-641, 1993

    Google Scholar 

  7. Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R: A multicenter randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal hemorrhage. Gut 41:526-533, 1997

    Google Scholar 

  8. D'Amico G, Politi F, Morabito A, D'Antoni A, Guerrera D, Giannuoli G, Traina M, Vizzini G, Pasta L, Pagliaro L: Liver Study Group of V Cervello Hospital: Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomised pragmatic trial. Hepatology 28:1206-1214, 1998

    Google Scholar 

  9. McCormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McIntyre N, Burroughs AK: Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 2:489-492, 1990

    Google Scholar 

  10. McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagstaff D, McIntyre N, Burroughs AK: Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A doubleblind, placebo controlled study. Hepatology 16:1180-1186, 1992

    Google Scholar 

  11. Abillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, Escartin P: Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 21:88-94, 1994

    Google Scholar 

  12. Huang YT, Tsai JF, Liu TB, Hong CY, Yang MC, Lin HC: Chronic administration of octreotide increases vascular responsiveness in rats with portal hypertension. Clin Sci 91:601-606, 1996

    Google Scholar 

  13. Huang YT, Cheng YR, Lin HC, Hou MC, Lee SD, Hong CY: Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats. Dig Dis Sci 43:358-364, 1998

    Google Scholar 

  14. Gosling RG, King DH, Newman DL: Transcutaneous measurement of arterial blood velocity by ultrasound. In Ultrasonics for Industry Conference Papers. Guildford, England. IPC, 1969, pp 16-32

    Google Scholar 

  15. Bolondi L, Gaiani S, Barbara L: Accuracy and reproducibility of portal flow measurement by Doppler US. J Hepatol 13:269-273, 1991

    Google Scholar 

  16. Nelson RC, Sherbourne GM, Spencer HB, Chezmar JL: Splenic venous flow exceeding portal venous flow at Doppler sonography: Relationship to portosystemic varices. AJR 161:563-567, 1993

    Google Scholar 

  17. Ludwig D, Brüning A, Terai S, Schaedel S, Feddersen A, Stange EF: Long-term hemodynamic and endocrine effects of octreotide on postprandial hyperemia in controls and cirrhotic patients: Randomised, double-blind, placebo-controlled study. Gastroenterology 114:A1293, 1998

    Google Scholar 

  18. Bernstein DP: Continuous noninvasive real-time monitoring of stroke volume and cardiac output by thoracic electrical bioimpedance. Crit Care Med 14:898-901, 1986

    Google Scholar 

  19. Appel PL, Kram HB, Mackabee J, Fleming AW, Shoemaker WC: Comparison of measurements of cardiac output by bioimpedance and thermodilution in severely ill surgical patients. Crit Care Med 14:933-935, 1996

    Google Scholar 

  20. Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F: The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 26:1018-1025, 1997

    Google Scholar 

  21. Sieber CC, Mosca PG, Groszmann RJ: Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 262:G274-G277, 1992

    Google Scholar 

  22. McCormick PA, Seifalian AM, Stansby G, McGann G, Collins P, Chin J, McIntyre N, Dick R, Burroughs AK: Superior mesenteric artery blood flow in man measured with intraarterial Doppler catheters: Effect of octreotide. J Hepatol 17:20-27, 1993

    Google Scholar 

  23. Harris AG: Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects. Gut 35:S1-S4, 1994

    Google Scholar 

  24. Li Y, Owyang C: Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 265:G251-G257, 1993

    Google Scholar 

  25. Ludwig D, Schwarting K, Korbel CM, Brüning A, Schiefer B, Stange EF: The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 28:631-638, 1998

    Google Scholar 

  26. MacMathuna MP: Mechanisms and consequences of portal hypertension. Drugs 44:S1-S13, 1992

    Google Scholar 

  27. Iwao T, Toyonaga A, Oho K, Sakai T, Tayama C, Masumoto H, Sato M, Nakahara K, Tanikawa K: Postprandial splanchnic hemodynamic response in patients with cirrhosis of the liver: Evaluation with “triple-vessel” duplex US. Radiology 201:711-715, 1996

    Google Scholar 

  28. Bendtsen F, Simonsen L, Henriksen JH: Effect on hemodynamics of a liquid meal alone and in combination with propranolol in cirrhosis. Gastroenterology 102:1017-1023, 1992

    Google Scholar 

  29. Taourel P, Blanc P, Dauzat M, Chabre M, Pradel J, Gallix B, Larrey D, Bruel J-M: Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis. Relationship between quantitative Doppler measurements and the severity of portal hypertension and liver failure. Hepatology 28:932-936, 1998

    Google Scholar 

  30. Kelbaek H, Munck O, Christensen NJ, Godtfredsen J: Central haemodynamics after a meal. Br Heart J 61:506-509, 1989

    Google Scholar 

  31. Gallavan RH, Chou CC, Kvietys P, Sit SP: Regional blood flow during ingestion in the conscious dog. Am J Physiol 238:H220-H225, 1980

    Google Scholar 

  32. O'Brien S, Keogan M, Patchett S, McCormick PA, Afdhal N, Hegarty JE: Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut 33:364-367, 1992

    Google Scholar 

  33. McCormick PA, Chin J, Greenslade L, Karatapanis S, Dick R, McIntyre N, Burroughs AK: Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 21:1255-1260, 1995

    Google Scholar 

  34. Pizcueta MP, Casamitjana R, Bosch J, Rodes J: Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: Role of hyperglucagonism. Am J Physiol 258:G191-G195, 1990

    Google Scholar 

  35. Sieber C, Beglinger C, Jaeger K, Hildebrand P, Stalder GA: Regulation of postprandial mesenteric blood flow in humans. Gut 32:361-366, 1991

    Google Scholar 

  36. Sabat M, Guarner C, Soriano G, Bulbena O, Novella TN, Ortiz J, Ricart E, Villanueva C, Rosello J, Rodriguez J, Balanzo J: Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 43:2184-2189, 1998

    Google Scholar 

  37. Pinzani, M, Milani S, de Franco R, Grappone C, Caligiuri A, Gentilini A, Tosti-Guerra C, Maggi M, Failli P, Ruocco C, Gentilini P: Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110:534-548, 1996

    Google Scholar 

  38. Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, Clozel M, Lebrec D: Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 28:655-659, 1998

    Google Scholar 

  39. Donckier J, Stoleru L, Selvais P, Galanti L, Van Mechelen H, Ketelslegers JM, Charlier AA: Effects of octreotide on cardiovascular hormones and haemodynamics in conscious dogs. J Endocrinol Invest 19:106-113, 1996

    Google Scholar 

  40. Moller S, Gulber V, Henriksen JH, Gerbes AL: Endothelin-1 an endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 23:135-144, 1995

    Google Scholar 

  41. Mottet C, Sieber CC, Nauer A, Drewe J, Fried R, Larsen F, Beglinger C: Hemodynamic effects of the somatostatin analog lanreotide in humans: Placebo-controlled, cross-over doseranging echo-Doppler study. Hepatology 27:920-925, 1998

    Google Scholar 

  42. Sieber CC, Lee FY, Groszmann RJ: Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology 23:1218-1223, 1996

    Google Scholar 

  43. Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, Rousselet MC, Rosenbaum J, Cales P: Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 28:1525-1531, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Department of Internal Medicine I, Division of Gastroenterology, University of L, L, Germany

    Diether Ludwig, Sabina Schãdel, Andreas Brũning & Bernhard Schiefer

Authors
  1. Diether Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabina Schãdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Brũning
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernhard Schiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduard F. Stange
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludwig, D., Schãdel, S., Brũning, A. et al. 48-Hour Hemodynamic Effects of Octreotide on Postprandial Splanchnic Hyperemia in Patients with Liver Cirrhosis and Portal Hypertension. Dig Dis Sci 45, 1019–1027 (2000). https://doi.org/10.1023/A:1005553914878

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005553914878

Search

Navigation